Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

First Horizon Advisors Inc. reduced its position in Merck & Co., Inc. by 8.7%, selling 15,566 shares in the 4th quarter, ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...